Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012;17(1):5-8.
doi: 10.1634/theoncologist.2011-0429. Epub 2012 Jan 10.

Cancer-associated isocitrate dehydrogenase mutations

Katharine E Yen  1 , David P Schenkein
Affiliations
Comment

Cancer-associated isocitrate dehydrogenase mutations

Katharine E Yen et al. Oncologist. 2012.

Abstract

The role of isocitrate dehydrogenase mutations as a therapeutic target for cancer therapy is examined.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Katharine E. Yen: Agios Pharmaceuticals (E, OI); David P. Schenkein: Agios Pharmaceuticals (E, OI).

Figures

Figure 1.
Figure 1.
Hypotheses linking 2-HG with cancer-relevant processes. Abbreviations: 2-HG, 2-hydroxyglutarate; 5-ALA, 5-aminolevulinic acid; 5mC, 5-methylcytosine; α-KG, α-ketoglutarate; CoA, coenzyme A; IDH, isocitrate dehydrogenase; OAA, oxaloacetate.
See this image and copyright information in PMC

Comment on

References

    1. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739–744. - PMC - PubMed
    1. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–773. - PMC - PubMed
    1. Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224:334–343. - PubMed
    1. Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of IDH1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. The Oncologist. 2012;17:72–79. - PMC - PubMed
    1. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19:17–30. - PMC - PubMed